Case Reports

Superior vena cava syndrome as an initial presentation of low-grade follicular lymphoma


 

Superior vena cava (SVC) syndrome refers to a constellation of symptoms produced by the obstruction of blood flow through the SVC, resulting in symptoms of dyspnea, facial and upper-extremity edema, cough, chest pain, and dysphagia.1 Malignancies represent 60%-85% of the etiologies of SVC syndrome. Cumulatively, lymphoma and lung cancer represent 95% of malignancy-related SVC syndrome etiologies, with non-small-cell lung cancer (NSCLC) reported in about 50% of cases, small-cell lung cancer (SCLC) in about 25%, and non-Hodgkin lymphoma (NHL) in 10 % of all cases.1,2

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

FDA approves idelalisib for three leukemia and lymphoma indications
B-Cell Lymphoma ICYMI
PET-CT better predicted follicular lymphoma survival
B-Cell Lymphoma ICYMI
Aspartame, sweetened drinks don’t increase risk of NHL
B-Cell Lymphoma ICYMI
CHMP recommends ibrutinib for CLL, MCL
B-Cell Lymphoma ICYMI
Maintenance may be unnecessary in FL
B-Cell Lymphoma ICYMI
Idelalisib approved to treat CLL, FL in EU
B-Cell Lymphoma ICYMI
FDA approves idelalisib for CLL, SLL and FL
B-Cell Lymphoma ICYMI
Study supports new gold standard for FL
B-Cell Lymphoma ICYMI
CHMP recommends idelalisib for CLL, FL
B-Cell Lymphoma ICYMI
Combo appears safe and active in CLL, NHL
B-Cell Lymphoma ICYMI